Pharmacogenetics in the Treatment of Cardiovascular Diseases and Its Current Progress Regarding Implementation in the Clinical Routine
Metadatos
Mostrar el registro completo del ítemAutor
Dávila Fajardo, Cristina Lucía; Díaz Villamarín, Xando; Antúnez Rodríguez, Alba; Fernández Gómez, Ana Estefanía; García Navas, Paloma; Martínez González, Luis Javier; Dávila Fajardo, José Augusto; Cabeza-Barrera, JoséEditorial
MDPI
Materia
pharmacogenetics clopidogrel warfarin
Fecha
2019-04-01Referencia bibliográfica
Dávila Fajardo, C.L. et. al. Genes 2019, 10(4), 261. [https://doi.org/10.3390/genes10040261]
Resumen
There is a special interest in the implementation of pharmacogenetics in clinical practice,
although there are some barriers that are preventing this integration. A large part of these
pharmacogenetic tests are focused on drugs used in oncology and psychiatry fields and for antiviral
drugs. However, the scientific evidence is also high for other drugs used in other medical areas, for
example, in cardiology. In this article, we discuss the evidence and guidelines currently available on
pharmacogenetics for clopidogrel, warfarin, acenocoumarol, and simvastatin and its implementation
in daily clinical practice.





